ATE247454T1 - Verwendung von wenigstens einem no-synthase hemmer zur behandlung empfindlicher haut - Google Patents

Verwendung von wenigstens einem no-synthase hemmer zur behandlung empfindlicher haut

Info

Publication number
ATE247454T1
ATE247454T1 AT96933468T AT96933468T ATE247454T1 AT E247454 T1 ATE247454 T1 AT E247454T1 AT 96933468 T AT96933468 T AT 96933468T AT 96933468 T AT96933468 T AT 96933468T AT E247454 T1 ATE247454 T1 AT E247454T1
Authority
AT
Austria
Prior art keywords
sensitive skin
synthase inhibitor
treat sensitive
treat
symptoms associated
Prior art date
Application number
AT96933468T
Other languages
English (en)
Inventor
Lionel Breton
Lacharriere Olivier De
Original Assignee
Oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9483954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE247454(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oreal filed Critical Oreal
Application granted granted Critical
Publication of ATE247454T1 publication Critical patent/ATE247454T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/43—Guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96933468T 1995-10-26 1996-10-01 Verwendung von wenigstens einem no-synthase hemmer zur behandlung empfindlicher haut ATE247454T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9512653A FR2740339B1 (fr) 1995-10-26 1995-10-26 Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
PCT/FR1996/001529 WO1997015280A1 (fr) 1995-10-26 1996-10-01 Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles

Publications (1)

Publication Number Publication Date
ATE247454T1 true ATE247454T1 (de) 2003-09-15

Family

ID=9483954

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96933468T ATE247454T1 (de) 1995-10-26 1996-10-01 Verwendung von wenigstens einem no-synthase hemmer zur behandlung empfindlicher haut

Country Status (9)

Country Link
US (1) US20020037854A1 (de)
EP (1) EP0859591B1 (de)
JP (1) JP3110050B2 (de)
AT (1) ATE247454T1 (de)
CA (1) CA2222303C (de)
DE (1) DE69629578D1 (de)
FR (1) FR2740339B1 (de)
NO (1) NO312272B1 (de)
WO (1) WO1997015280A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998036730A2 (de) * 1997-02-21 1998-08-27 Beiersdorf Ag Zubereitungen für die behandlung von rosacea
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
FR2778562B1 (fr) * 1998-05-14 2000-08-04 Sephra Composition pharmaceutique, hygienique et/ou cosmetique contenant de l'eau de mer et de l'arginine
GR1003146B (el) * 1998-06-23 1999-06-02 Μεθοδος εξουδετερωσης των πολεμικων χημικων αεριων της μουσταρδας, της σαρινης και του δερματικου ερυθηματος απο την υπεριωδη ακτινοβολια του ηλιου με την χρησιμοποιηση αναστολεων των ελευθερων ριζων
DE19918750A1 (de) * 1999-04-24 2000-10-26 Beiersdorf Ag Wirkstoffe, kosmetische und dermatologische Zubereitungen für die Verbesserung der Barrierefunktion
DE19945484A1 (de) * 1999-09-22 2001-04-05 Kolb Bachofen Victoria NO-freisetzende topisch applizierbare Zusammensetzung
DE19962267A1 (de) * 1999-12-23 2001-06-28 Beiersdorf Ag Verwendung von Wirkstoffkombinationen aus einem oder mehreren NO-Synthasehemmern und einer oder mehreren Ascorbylverbindungen zur Stärkung der Barrierefunktion der Haut
DE10000840A1 (de) * 2000-01-12 2001-07-19 Beiersdorf Ag Verwendung eines oder mehrerer NO-Synthasehemmer
JP2001233764A (ja) * 2000-02-22 2001-08-28 Hisamitsu Pharmaceut Co Inc Ｎ−置換−ｏ−トルイジン誘導体からなる鎮痒剤
FR2808190B1 (fr) * 2000-04-28 2002-06-21 Oreal Extrait de vegetal de l'espece vitis vinifera comme inhibiteur de no-synthase et utilisations
FR2808189B1 (fr) * 2000-04-28 2004-03-05 Oreal Lipochroman-6 comme inhibiteur de no-synthase et utilisations
FR2811567B1 (fr) * 2000-07-13 2003-01-17 Oreal Composition, notamment cosmetique, comprenant la dhea et/ou un precurseur ou derive de celle-ci, en association avec au moins un inhibiteur de no-synthase
DE10047204A1 (de) * 2000-09-23 2002-04-25 Henkel Kgaa Topische Hautbehandlungsmittel mit Arginase
FR2818136B1 (fr) * 2000-12-15 2004-10-15 Oreal Composition, notamment cosmetique, comprenant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un inhibiteur de no-synthase
DE10111050A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthase des warmblütigenOrganismus ihre Wirkung entfaltet, zur Herstellung von kosmetischewn oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe unerwünschter Hautpigmentierung
DE10111049A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen, zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter trockener Haut
DE10111054A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Stärkung der Barrierefunktion der Haut
DE10111052A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthase des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Steigerung der Ceramidbiosynthese
FR2825920B1 (fr) * 2001-06-15 2006-04-28 Oreal Desferal comme inhibiteur de no-synthase et utilisations
FR2825921B1 (fr) * 2001-06-15 2005-02-11 Oreal Inhibiteur de no-synthase et utilisations
FR2825923B1 (fr) * 2001-06-15 2006-04-07 Oreal Inhibiteur de no-synthase et utilisations
CA2456035A1 (fr) * 2003-02-03 2004-08-03 L'oreal Utilisation de n-arylmethylene ethylenediaminetriacetates, n-arylmethyleneiminodiacetates ou n,n'-diarylmethylene ethylenediamineacetates comme donneurs de no
FR2850578B1 (fr) * 2003-02-03 2006-07-28 Oreal Utilisation de n-arylmethylene ethylenediaminetriacetates, n-arylmethyleneiminodiacetates ou n,n'-diarylmethylene ethylenediamineacetates comme donneurs de no
CA2556967A1 (en) * 2004-02-23 2005-09-09 Strategic Science & Technologies, Llc Topical delivery of a nitric oxide donor to improve body and skin appearance
US20090105336A1 (en) * 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
JP2007532697A (ja) 2004-04-19 2007-11-15 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー 局所的血流増大の有益な効果
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US8222283B2 (en) * 2005-05-17 2012-07-17 Santen Pharmaceutical Co., Ltd. Method for treating a keratoconjunctival disorder
EP1749528A1 (de) * 2005-08-05 2007-02-07 Pharma C S.A. Pharmazeutische Kombinationen, welche mu-opioid Agonisten und Inhibitoren der Stickstoffmonoxidherstellung enthalten
KR20100016140A (ko) * 2007-05-25 2010-02-12 산텐 세이야꾸 가부시키가이샤 가령 황반 변성의 예방 또는 치료제
CA2716466A1 (en) * 2008-02-28 2009-09-03 Santen Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for eye disease accompanied by optic nerve disorder
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
WO2010151241A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing naproxen
RU2505291C2 (ru) 2009-06-24 2014-01-27 СТРАТЕДЖИК САЙЕНС ЭНД ТЕКНОЛОДЖИЗ, ЭлЭлСи Топическая композиция, содержащая ибупрофен
JP2014501283A (ja) 2010-12-29 2014-01-20 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー アレルギーおよび他の適応症の処置のためのシステムおよび方法
ES2811515T3 (es) 2010-12-29 2021-03-12 Strategic Science & Tech Llc Tratamiento de disfunción eréctil y otras indicaciones
JP2019508411A (ja) * 2016-02-11 2019-03-28 オハイオ ユニバーシティ 構成型一酸化窒素合成酵素（ｃＮＯＳ）を標的とすることによる、ＵＶＢ照射傷害を阻害するための組成物及び方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0096521A3 (de) * 1982-06-01 1985-01-23 THE PROCTER & GAMBLE COMPANY Enthaarungsmittel
DE3620674A1 (de) * 1986-06-20 1987-12-23 Nattermann A & Cie Salbe zur behandlung von hauterkrankungen
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US5449688A (en) * 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases
GB9312204D0 (en) * 1993-06-14 1993-07-28 Zeneca Ltd Therapeutic composition
CA2176747A1 (en) * 1993-11-17 1995-05-26 J. Brice Weinberg Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases
DK0957087T3 (da) * 1994-06-15 2003-03-24 Wellcome Found Intermediater, der er anvendelige til fremstilling af enzym-inhibitorer

Also Published As

Publication number Publication date
CA2222303C (fr) 2003-01-14
EP0859591A1 (de) 1998-08-26
NO976142L (no) 1998-06-03
US20020037854A1 (en) 2002-03-28
JPH10511404A (ja) 1998-11-04
EP0859591B1 (de) 2003-08-20
WO1997015280A1 (fr) 1997-05-01
DE69629578D1 (de) 2003-09-25
FR2740339A1 (fr) 1997-04-30
CA2222303A1 (fr) 1997-05-01
JP3110050B2 (ja) 2000-11-20
FR2740339B1 (fr) 1997-12-05
NO976142D0 (no) 1997-12-30
NO312272B1 (no) 2002-04-22

Similar Documents

Publication Publication Date Title
DE69629578D1 (de) Verwendung von wenigstens einem no-synthase hemmer zur behandlung empfindlicher haut
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69428813D1 (de) Verwendung von Botulinustoxin zur Behandlung von Spannungs-Kopfschmerz
NO973900D0 (no) Nitrogenoksyd syntase inhibitorer
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
NO962568L (no) Anvendelse av PLA2 inhibitorer som behandling for Alzheimers sykdom
ES2038609T3 (es) 4,5-dihidroisoxazol, 3,5 disustituido como inhibidores de transglutaminasa.
DE69727695D1 (de) Verwendung von matrix-metalloproteinase inhibitoren zur förderung der wundheilung
DE69532804D1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
DE602004003587D1 (de) Kosmetische verwendung einer zusammensetzung mit mindestens einem oxazolin als wirkstoff, als abnehmprodukt und/oder zur prävention und/oder behandlung von cellulite
ATE278382T1 (de) Verwendung von ellagsäure zum schutz gegen verschmutzung
NO994330D0 (no) Metode for behandling av en tumor
DE69331833D1 (de) Verwendung von vitamin d-glykosiden zur behandlung oder prävention von osteoporose
DE69331546D1 (de) Verwendung von cytochrome - p 450 - inhibitoren zur hemmung des stoffwechsels von stickstoffsubstituierten acridinen
DE69429013D1 (de) Verwendung von dimeticon zur behandlung der konstipation
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
DE60219761D1 (de) Verwendung von quetiapin für die behandlung von kokain-abhängigkeit
SE9301606D0 (sv) Composition for the treatment of impaired hair growth
DE69430545D1 (de) Verwendung von penciclovir zur behandlung von postherpetischer neuralgie
ATE365718T1 (de) Substituierte 11-phenyl-dibenzazepin-verbindungen,die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten
ATA96097A (de) Verwendung von queller zur behandlung oder prophylaxe von jodmangelerscheinungen
ATE225660T1 (de) Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz
ATE302605T1 (de) Tazaroten und uvb-phototherapie zur behandlung von psoriasis
DE69802828D1 (de) Verwendung von 6,7-substituierter 2-aminotetraline zur behandlung von zytokin-vermittleten entzündungszuständen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties